- Home
- NVNO vs IVVD Comparison
NVNO vs IVVD Comparison
Compare NVNO & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNO
- IVVD
- Stock Information
- Founded
- NVNO 1987
- IVVD 2020
- Country
- NVNO United States
- IVVD United States
- Employees
- NVNO N/A
- IVVD N/A
- Industry
- NVNO Medical/Dental Instruments
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- NVNO Health Care
- IVVD Health Care
- Exchange
- NVNO Nasdaq
- IVVD Nasdaq
- Market Cap
- NVNO 58.9M
- IVVD 66.6M
- IPO Year
- NVNO N/A
- IVVD 2021
- Fundamental
- Price
- NVNO $3.15
- IVVD $0.39
- Analyst Decision
- NVNO
- IVVD Strong Buy
- Analyst Count
- NVNO 0
- IVVD 4
- Target Price
- NVNO N/A
- IVVD $7.89
- AVG Volume (30 Days)
- NVNO 147.8K
- IVVD 1.7M
- Earning Date
- NVNO 02-27-2025
- IVVD 11-14-2024
- Dividend Yield
- NVNO N/A
- IVVD N/A
- EPS Growth
- NVNO N/A
- IVVD N/A
- EPS
- NVNO N/A
- IVVD N/A
- Revenue
- NVNO N/A
- IVVD $11,564,000.00
- Revenue This Year
- NVNO N/A
- IVVD N/A
- Revenue Next Year
- NVNO N/A
- IVVD $468.95
- P/E Ratio
- NVNO N/A
- IVVD N/A
- Revenue Growth
- NVNO N/A
- IVVD N/A
- 52 Week Low
- NVNO $2.45
- IVVD $0.38
- 52 Week High
- NVNO $6.97
- IVVD $5.20
- Technical
- Relative Strength Index (RSI)
- NVNO 46.80
- IVVD 38.93
- Support Level
- NVNO $3.13
- IVVD $0.41
- Resistance Level
- NVNO $3.68
- IVVD $0.50
- Average True Range (ATR)
- NVNO 0.21
- IVVD 0.06
- MACD
- NVNO -0.01
- IVVD 0.01
- Stochastic Oscillator
- NVNO 8.20
- IVVD 3.12
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.